0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Myrexis
Its shares trade under the ticker MYRX. It has been listed since 12 June 2009.
Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. The company is headquartered in New York City, New York. The company went IPO on 2009-06-12. The firm was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The firm determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The firm operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jun 2009
- Employees
- 1
- Website
- myrexis.com ↗
Leadership
Pay as last reported
- Mr. Jonathan CouchmanPresident, Chief Executive Officer, Chief Financial Officer, Director, since 2013$1
- Andrea KendellTreasurer, Secretary$894,121
- Michael PearceIndependent Director
- Mr. Steven ScheiweIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Myrexis Inc employs 1 full-time employee in New York City.
- Myrexis focuses on life sciences assets in oncology and autoimmune diseases.
- Myrexis generated a pipeline of differentiated drug candidates in the Health Care sector.
Weaknesses
- Myrexis suspended all development activity on preclinical and clinical programs in February 2012.
- Myrexis has no revenue streams from commercial products as of 2012.
- Myrexis operates solely within the United States with no international presence.
Opportunities
- Myrexis aims to acquire commercial-stage biopharmaceutical assets to build a commercial company.
- Myrexis can pursue strategic alternatives to enhance shareholder value through investment banking.
- Myrexis targets life sciences assets in the Health Care industry for growth.
Threats
- Myrexis faces challenges in developing new drug candidates without active clinical programs.
- Myrexis has limited resources due to a single full-time employee.
- Myrexis must navigate the competitive biopharmaceutical market without a commercial product.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.